Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The dynamics of telomere length in primary and metastatic colorectal cancer lesions

M. Kroupa, O. Kubecek, K. Tomasova, P. Hanak, M. Krupova, K. Cervena, A. Siskova, J. Rosendorf, P. Hosek, L. Vodickova, P. Vodicka, V. Liska, S. John, V. Vymetalkova, J. Petera

. 2023 ; 13 (1) : 9097. [pub] 20230605

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23011110

Telomeric sequences, the structures comprised of hexanucleotide repeats and associated proteins, play a pivotal role in chromosome end protection and preservation of genomic stability. Herein we address telomere length (TL) dynamics in primary colorectal cancer (CRC) tumour tissues and corresponding liver metastases. TL was measured by multiplex monochrome real-time qPCR in paired samples of primary tumours and liver metastases along with non-cancerous reference tissues obtained from 51 patients diagnosed with metastatic CRC. Telomere shortening was observed in the majority of primary tumour tissues compared to non-cancerous mucosa (84.1%, p < 0.0001). Tumours located within the proximal colon had shorter TL than those in the rectum (p < 0.05). TL in liver metastases was not significantly different from that in primary tumours (p = 0.41). TL in metastatic tissue was shorter in the patients diagnosed with metachronous liver metastases than in those diagnosed with synchronous liver metastases (p = 0.03). The metastatic liver lesions size correlated with the TL in metastases (p < 0.05). Following the neoadjuvant treatment, the patients with rectal cancer had shortened telomeres in tumour tissue than prior to the therapy (p = 0.01). Patients with a TL ratio between tumour tissue and the adjacent non-cancerous mucosa of ≥ 0.387 were associated with increased overall survival (p = 0.01). This study provides insights into TL dynamics during progression of the disease. The results show TL differences in metastatic lesions and may help in clinical practice to predict the patient's prognosis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011110
003      
CZ-PrNML
005      
20230801132819.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-023-35835-9 $2 doi
035    __
$a (PubMed)37277368
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kroupa, Michal $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic. michal.kroupa@iem.cas.cz $u Biomedical Centre, Faculty of Medicine in Pilsen Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic. michal.kroupa@iem.cas.cz
245    14
$a The dynamics of telomere length in primary and metastatic colorectal cancer lesions / $c M. Kroupa, O. Kubecek, K. Tomasova, P. Hanak, M. Krupova, K. Cervena, A. Siskova, J. Rosendorf, P. Hosek, L. Vodickova, P. Vodicka, V. Liska, S. John, V. Vymetalkova, J. Petera
520    9_
$a Telomeric sequences, the structures comprised of hexanucleotide repeats and associated proteins, play a pivotal role in chromosome end protection and preservation of genomic stability. Herein we address telomere length (TL) dynamics in primary colorectal cancer (CRC) tumour tissues and corresponding liver metastases. TL was measured by multiplex monochrome real-time qPCR in paired samples of primary tumours and liver metastases along with non-cancerous reference tissues obtained from 51 patients diagnosed with metastatic CRC. Telomere shortening was observed in the majority of primary tumour tissues compared to non-cancerous mucosa (84.1%, p < 0.0001). Tumours located within the proximal colon had shorter TL than those in the rectum (p < 0.05). TL in liver metastases was not significantly different from that in primary tumours (p = 0.41). TL in metastatic tissue was shorter in the patients diagnosed with metachronous liver metastases than in those diagnosed with synchronous liver metastases (p = 0.03). The metastatic liver lesions size correlated with the TL in metastases (p < 0.05). Following the neoadjuvant treatment, the patients with rectal cancer had shortened telomeres in tumour tissue than prior to the therapy (p = 0.01). Patients with a TL ratio between tumour tissue and the adjacent non-cancerous mucosa of ≥ 0.387 were associated with increased overall survival (p = 0.01). This study provides insights into TL dynamics during progression of the disease. The results show TL differences in metastatic lesions and may help in clinical practice to predict the patient's prognosis.
650    _2
$a lidé $7 D006801
650    12
$a nádory tračníku $7 D003110
650    12
$a nádory rekta $7 D012004
650    _2
$a prognóza $7 D011379
650    12
$a nádory jater $7 D008113
650    _2
$a telomery $x genetika $x patologie $7 D016615
650    12
$a kolorektální nádory $x patologie $7 D015179
650    _2
$a zkracování telomer $7 D059506
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kubecek, Ondrej $u Department of Oncology and Radiotherapy, Charles University, Medical Faculty and University Hospital in Hradec Kralove, Simkova 870, 500 38, Hradec Kralove, Czech Republic
700    1_
$a Tomasova, Kristyna $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic
700    1_
$a Hanak, Petr $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic
700    1_
$a Krupova, Marketa $u The Fingerland Department of Pathology, University Hospital in Hradec Kralove, Sokolska 581, 50005, Hradec Kralove, Czech Republic
700    1_
$a Cervena, Klara $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic $u Institute of Biology and Medical Genetics, 1St Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic
700    1_
$a Siskova, Anna $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic $u Institute of Biology and Medical Genetics, 1St Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic
700    1_
$a Rosendorf, Jachym $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic
700    1_
$a Hosek, Petr $u Biomedical Centre, Faculty of Medicine in Pilsen Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic
700    1_
$a Vodickova, Ludmila $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic $u Institute of Biology and Medical Genetics, 1St Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic
700    1_
$a Vodicka, Pavel $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic $u Institute of Biology and Medical Genetics, 1St Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic
700    1_
$a Liska, Vaclav $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic
700    1_
$a John, Stanislav $u Department of Oncology and Radiotherapy, Charles University, Medical Faculty and University Hospital in Hradec Kralove, Simkova 870, 500 38, Hradec Kralove, Czech Republic
700    1_
$a Vymetalkova, Veronika $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic $u Institute of Biology and Medical Genetics, 1St Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic
700    1_
$a Petera, Jiri $u Department of Oncology and Radiotherapy, Charles University, Medical Faculty and University Hospital in Hradec Kralove, Simkova 870, 500 38, Hradec Kralove, Czech Republic
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 13, č. 1 (2023), s. 9097
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37277368 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132816 $b ABA008
999    __
$a ok $b bmc $g 1963484 $s 1197375
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 13 $c 1 $d 9097 $e 20230605 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options